Uso de resúmenes de evidencia para informar el tratamiento farmacológico de personas con sospecha o diagnóstico de infección respiratoria por SARS-CoV-2/COVID-19

Palabras clave: COVID-19, síndrome respiratorio agudo grave, tratamiento farmacológico, antivirales, SARS-CoV-2.

Resumen

Introducción: debido a la emergencia del coronavirus SARS-CoV-2 desde diciembre del 2019, se ha generado un gran volumen de producción científica, en algún caso incierta o controvertida especialmente en el manejo farmacológico de los pacientes con esta infección; por lo tanto, se considera relevante buscar alternativas metodológicas para realizar su síntesis rigurosa, sistemática y de calidad, pero con menor tiempo de ejecución y menor costo.

Objetivo: presentar la evidencia disponible respecto al manejo farmacológico de personas con sospecha o diagnóstico de infección respiratoria por SARS-CoV-2 (COVID-19) utilizando el método de revisiones sistemáticas rápidas (RS-R) en medicamentos poten- cialmente eficaces para su manejo.

Metodología: se realizó una búsqueda sistemática y estructurada en Medline, Embase, Scopus, Cochrane Library, Clinical trials y Google Scholar en inglés. Los estudios incluidos fueron guías de práctica clínica, consensos, revisiones sistemáticas, metaanálisis, ensayos clínicos y otros estudios primarios. La búsqueda y extracción de datos se realizó por múltiples revisores, pero ninguna fue pareada.

Resultados: dieciseis preguntas de interés clínico fueron resueltas, relacionadas con el uso en COVID-19 de lopinavir/ ritonavir, nelfinavir, oseltamivir, remdesivir, ribavirina, teicoplanina, umifenovir, favipiravir, tocilizumab, ivermectina y plasma convaleciente; también se evaluó el uso de medicamentos de soporte e incluidos en el manejo como la dexametasona, así como el uso concomitante de medicamentos que generaron dudas como son los AINES, los IECA y los ARA II.

Conclusiones: los resúmenes de evidencia se muestran dentro del escenario de la pandemia como una buena alternativa metodológica para ofrecer información de calidad a corto plazo para los tomadores de decisiones.

Descargas

La descarga de datos todavía no está disponible.

Referencias

Munn Z, Lockwood C, Moola S. The Development and Use of Evidence Summaries for Point of Care Information Systems: A Streamlined Rapid Review Approach. Worldviews Evid Based Nurs. 2015;12(3):131-38. Available from: https://doi.org/10.1111/wvn.12094.

Andermann A, Pang T, Newton JN, Davis A, Panisset U. Evidence for Health II: Overcoming barriers to using evidence in policy and practice. Heal Res Policy Syst. 2016;14(17): Available from: https://doi.org/10.1186/s12961-016-0086-3

Patnode CD, Eder ML, Walsh ES, Viswanathan M, Lin JS. The Use of Rapid Review Methods for the U.S. Preventive Services Task Force. Am J Prev Med. 2018;54(1S1):S19-25. Available from: https://doi.org/10.1016/j.amepre.2017.07.0

Tricco AC, Langlois E V, Straus SE. World Health Organization, Alliance for Health Policy and Systems Research. Rapid Reviews To Strengthen Health Policy and Systems: a Practical Guide [Internet]. 2017. Available from: https://www.who.int/alliance-hpsr/resources/ publications/rapid-review-guide/en/

Gutierrez I. Protocolos de búsqueda bibliográfica. Vitoria-Gasteiz [Internet]. España; 2002. Available from: https://www.osakidetza.euskadi. eus/contenidos/informacion/osteba_formacion_/es_def/adjuntos bibliografia.pdf

Dobbins M. Rapid Review Guidebook. Steps for conducting a rapid review [Internet]. Canada: National Collaborating Centre for Methods and Tools; 2017. 25 p. Available from: https://www.nccmt.ca/uploads/media/media/0001/01/a816af720e4d587e13da6bb307df8c907a5dff9a.pdf

Lehoux P, Tailliez S, Denis JL, Hivon M. Redefining health technology assessment in Canada: Diversification of products and contextualization of findings. Int J Technol Assess Health Care. 2004;20(3):325-36. Available from: https://doi.org/10.1017/s026646230400114x

Keralty. Instituto Global de Excelencia Clínica. Manual de revisiones sistemáticas rápidas. Colombia; 2019. 9. Agencia Española de Medicamentos y Productos Sanitarios. La AEMPS informa que ningún dato indica que el ibuprofeno agrave las infecciones por COVID-19 [Internet]. 2020. p. 1. Available from: https://www.aemps.gob.es/informa/notasinformativas/ medicamentosusohumano-3/2020-medicamentosusohumano-3/la-aemps-informa-que-ningun-dato-indica-que-el-ibuprofeno-agrave-las-infecciones-por-covid-19/

Little P, Moore M, Kelly J, Williamson I, Leydon G, McDermott L, et al. Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial. BMJ. 2013;347(f6041). Available from: https://doi.org/10.1136/bmj.f6041

Basille D, Plouvier N, Trouve C, Duhaut P, Andrejak C, Jounieaux V. Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study. Lung. 2017;195(2):201-8. Available from: https://doi.org/10.1007/s00408-016-9973–1

Organización Mundial de la Salud (OMS). The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 [Internet]. 2020 [cited 2020 Jul 29]. Available from: https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal- anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19

National Institutes for Clinical Excellence (NICE) [Internet]. 2020 [cited 2020 Jul 30]. Available from: https://www.nice.org.uk/advice/es23/evidence/evidence-review-pdf-8717218669

Yousefifard M, Zali A, Zarghi A, Madani Neishaboori A, Hosseini M SS. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence. Int J Clin Pr [Internet]. 2020;e13557. Available from: https://doi.org/10.1111/ijcp.13557

Sodhi M, Khosrow-Khavar F, FitzGerald JM EM. Non-Steroidal Anti-Inflammatory Drugs and the Risk of Pneumonia Complications: A Systematic Review. Pharmacotherapy [Internet]. 2020. Available from: https://doi.org/10.1002/phar.2451

American College of Cardiology. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 [Internet]. 2020. Available from: https://www.acc.org/latest-in-cardiology/articles 2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns- re-using-raas-antagonists-in-covid-19

European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers [Internet]. 2020. Available from: https://www.escardio.org/Councils Council-on-Hypertension-(CHT)/News/position-statement- of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. Available from:https://doi.org/10.1016/S2213-2600(20)30116-8

Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020; 525(1):135-140. Available from: https://doi.org/10.1016/j.bbrc.2020.02.071

Schneider M, Ackermann K, Stuart M, Wex C, Protzer U, Schätzl HM, et al. Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain. J Virol. 2012;86(18):10112-22. Available from: https://doi.org/10.1128/JVI.01001-12

Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59. Available from: https://doi.org/10.3390/v11010059

Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Dexamethasone for COVID-19-Preliminary Report Effect of Dexamethasone in Hospitalized Patients with COVID-19 - Preliminary Report. medRxiv Internet]. 2020. Available from: https:// www.medrxiv.org/content/10.1101/2020.06.22.20137273v1.full.pdf

RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med [Internet]. 2020; Available from: https://www.nejm.org/doi/pdf/10.1056/ NEJMoa2021436?articleTools=true

National Institutes of Health. Corticosteroids | Coronavirus Disease COVID-19 [Internet]. [cited 2020 Jul 11]. Available from: https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/immunomodulators/corticosteroids/

Organización Mundial de la Salud. Preguntas y respuestas sobre la dexametasona y la COVID-19 [Internet]. [cited 2020 Jul 11]. Available from: https://www.who.int/es/news-room/q-a-detail/q-a-dexamethasone-and-covid-19

Institut national d’excellence en santé et en services sociaux (INESSS). COVID-19 et dexaméthasone [Internet]. 2020 [cited 2020 Jul 11]. p. 1-39. Available from: https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-19_INESSS_Dexamethasone.pdf

Search of: dexamethasone | covid-19 - List Results - ClinicalTrials.gov [Internet]. [cited 2020 Jul 17]. Available from: https://www.clinicaltrials.gov/ct2/results?cond=covid-19&term=dexamethasone&cntry=&state=&city=&dist=

Johnson DB, Lopez MJ KB. Dexamethasone - StatPearls - NCBI Bookshelf [Internet]. [cited 2020 Aug 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482130/

Polderman JAW, Farhang-Razi V, van Dieren S, Kranke P, DeVries JH, Hollmann MW, et al. Adverse side-effects of dexamethasone in surgical patients – an abridged Cochrane systematic review. Anaesthesia. 2019;74(7):929-39. Available from: https://doi.org/10.1111/anae.14610

Ferner R, DeVito N. AJ. Dexamethasone. Centre for Evidence-Based Medicine. Oxford University [Internet]. [cited 2020 Jul 11]. Available from: https://www.cebm.net/covid-19/dexamethasone/

Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J Int AIDS Soc. 2020;23(4):1-9. Available from: https://doi.org/10.1002/jia2.25489

Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ. 2020;192(27):E734-44. Available from: https://doi.org/10.1503/cmaj.200647

Jarvis B, Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs. 1998;56(1):147-67. Available from: https://doi.org/10.2165/00003495-199856010

Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS- associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719-25. Available from: https://doi.org/10.1016/j.bbrc.2004.04.083

Agencia Española de Medicamentos y Productos Sanitarios. Oseltamivir. Ficha técnica. [Internet]. Available from: https://cima.aemps.es/cima/pdfs/ft/02222003/FT_02222003.pdf

Li H, Wang YM, Xu JY, Cao B. [Potential antiviral therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E002. Available from: https://doi.org/10.3760/cma.j.issn.1001-0939

ClinicalTrials.gov. A Prospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia. ClinicalTrials.gov. NCT0425501. Available from: https://clinicaltrials.gov/ct2/show/NCT04255017

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med. 2020. Available from: https://doi.org/10.1056/NEJMoa2007764

Wang Y, Zhang D, Du PG, Du PR, Zhao PJ, Jin PY, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78. Available from: https://doi.org/10.1016/S0140-6736(20)310

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid- 19. N Engl J Med. 2020;NEJMoa2015301. Available from: https://doi.org/ 10.1056/NEJMoa2015301

Food and Drug Administration. FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF VEKLURY® (remdesivir) [Internet]. [cited 2020 Aug 1]. Available from: https://www.fda.gov/media/137566/download

European Medicines Agency. First COVID-19 treatment recommended for EU authorisation [Internet]. [cited 2020 Aug 1]. Available from: https://www.ema.europa.eu/en/documents/press-release/first-covid-19-treatment-recommended-eu-authorisation_en.pdf

National Institutes of Health. Remdesivir | Coronavirus Disease COVID-19 [Internet]. [cited 2020 Jul 27]. Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/

National Institute for Health and Care Excellence. Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 [Internet]. [cited 2020 Aug 1]. Available from: https://www.nice.org.uk/advice/es27/evidence/evidence-review-pdf-8771329261

Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. Available from: https://doi.org/10.1016/j.lfs.2020.117477

Elfiky A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020;253:117592 Available from: https://doi.org/10.1016/j.lfs.2020.117592

ClinicalTrials.gov. Ribavirin [Internet]. Available from: https://clinicaltrials.gov/ct2/results?cond=Coronavirus&term=Ribavirin&cntry=&state=&city=&dist=48. Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/ lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem. 2016;291(17):9218-32. Available from: https://doi.org/10.1074/jbc.M116.716100

Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents. 2020;55(4):105944. Available from: https://doi.org/10.1016/j.ijantimicag.2020.105944

Balzarini J, Keyaerts E, Vijgen L, Egberink H, De Clercq E, Van Ranst M, et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res. 2006;72(1):20-33. Available from: https://doi.org/10.1016/j.antiviral.2006.03

Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. 2020. Available from: https://doi.org/10.1101/2020.02.05.935387

Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, et al. Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167:45-67. Available from: https://doi.org/10.1016/j.antiviral.2019.04.006

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. Available from: https://doi.org/10.5582/ddt.2020.01012

Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64-8. Available from: https://doi.org/10.5582/bst.2020.01030

Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020;81(1):e1-e5. Available from: https://doi.org/10.1016/j.jinf.2020.03.002

Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2020;10.1002/jmv.26256. Available from: https://doi.org/10.1002/jmv.26256

Du YX CX. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020;108(2):242-47. Available from: https://doi.org/10.1002/cpt.1844

Agenzia Italiana del Farmaco. AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull’efficacia [Internet]. 2020 [cited 2020 Apr 19]. Available from: https://www.aifa.gov.it/-/aifa-precisa-uso-favipiravir- per-covid-19-non-autorizzato-in-europa-e-usa-scarse-evidenze-scientifiche-sull-efficacia

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020; Mar 18. Available from: https://doi.org/10.1016/j.eng.2020.03.007

Chang Chen, Yi Zhang, Jianying Huang, Ping Yin, Zhenshun Cheng, Jianyuan Wu et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv Prepr [Internet]. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4

ClinicalTrials.gov. Favipiravir [Internet]. 2020 [cited 2020 Jul 27]. Available from: https://www.clinicaltrials.gov/ct2/results?term=favipiravir&cond=Covid19&age_v=&gndr=&type=&rslt=&phase=2&phase=3&Search=Apply

Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS SF. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. J Med Virol [Internet]. 2020;10.1002/jmv.26038. Available from: https://doi.org/10.1002/jmv.26038

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev [Internet]. 2020;19(7). Available from: https://doi.org/10.1016/j.autrev.2020.102568

Sciascia, S., Aprà, F., Baffa, A., Baldovino, S., Boaro, D., Boero R. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020;38(3):529-32

Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36-42. Available from: https://doi.org/10.1016/j.ejim.2020.05.011

Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2020. Available from: https://doi.org/10.1101/2020.03.30.20048058

Panamerican Health Organization. PAHO. Ongoing living update of potential COVID-19 therapeutics: summary of rapid systematic reviews [Internet]. 2020 [cited 2020 Jun 18]. Available from: https://www.paho.org/en/file/66960/download?token=VVOvtH9l

Patel Amit DS. Ivermectin in COVID-19 Related Critical Illness [Internet]. 2020 [cited 2020 Apr 6]. Available from: http://dx.doi.org/10.2139/ssrn.3570270

Patel A. Usefulness of Ivermectin in COVID-19 Illness [Internet]. 2020 [cited 2020 Apr 19]. Available from: https://ssrn.com/abstract=3580524

Panamerican Health Organization. Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews [Internet]. 2020 [cited 2020 Apr 28]. Available from: https://iris.paho.org bitstream/handle/10665.2/52025/PAHOIMSCovid19200008_eng.pdf?sequence=1&isAllowed=y

Bray, M., Rayner, C., Noël, F., Jans, D., & Wagstaff K. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res [Internet]. 2020;104805. Available from: https://doi.org/10.1016/j.antiviral.2020.104805

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res [Internet]. 2020;104787. Available from: https://doi.org/10.1016/j.antiviral.2020.104787

Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin ?/?1 heterodimer. Antiviral Res. 2020.

Schmith, V. D., Zhou, J. J., & Lohmer LR. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther [Internet]. 2020;10.1002/cpt.1889. Available from: https://doi.org/10.1002/cpt.1889

Pimenoff VN, Elfstrom M, Dillner J. A systematic review of convalescent plasma treatment for COVID19. medRxiv. 2020. Available from: https://doi.org/10.1101/2020.06.05.20122820

Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, Lamikanra A, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;5(5):CD013600. Available from: https://doi.org/10.1002/14651858.CD013600

Instituto de Efectividad Clínica y Sanitaria. Plasma de convalecientes en COVID-19 [Internet]. Argentina; 2020 [cited 2020 May 25]. Available from: https://www.iecs.org.ar/wp-content/uploads/IECS-IRR-771-VA-Plasma-convalecientes-COVID-19-2.pdf

INESSS. COVID-19 et thérapie passive par anticorps (plasma convalescent) [Internet]. 2020 [cited 2020 May 24]. p. 1-14. Available from: https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-9_Plasma_convalescent.pdf

Health Technology Wales. Plasmapheresis of convalescent plasma to confer passive immunity [Internet]. 2020 [cited 2020 May 26]. p. 1-10. Available from: https://www.healthtechnology.wales/wp-content/uploads/2020/05/TER-203-CPT-v1.0.pdf

Canadian Agency for Drugs and Technologies in Health (CADTH). Convalescent Plasma Therapy for the Treatment of COVID-19: Clinical Effectiveness [Internet]. 2020 [cited 2020 May 23]. p. 1-14. Available from: https://cadth.ca/sites/default/files/covid-19/RA1113 Convalescent Plasma COVID.pdf

Agency for Care and Effectiveness and Ministry of Health Singapore. Should convalescent plasma be used for COVID-19? [Internet]. 2020 [cited 2020 May 22]. p. 1-6. Available from: https://www.moh.gov.sg docs/librariesprovider5/clinical-evidence-summaries/convalescent-plasma-infusion-for-covid-19-(updated-18-may-2020).pdf

Publicado
2020-04-14
Cómo citar
1.
Yomayusa González N, Low Padilla E, de la Hoz Siegler I, Chacón K, Acevedo Peña J, Barrero Garzón L, Barrera Barinas A, Tolosa Pérez N, Castillo Niuman A, Guevara Pulido F, Castelblanco Cuevas D, Pinzón Flórez C, Mendivelso Duarte F, Cantor Cruz F, Castillo Gutiérrez A, Gómez Gómez O, Ávila A, Guevara C, Álvarez Moreno C, Rojas Gambasica J, Arbeláez Duque CM, García Guarín B, Cárdenas Rodríguez M, Robayo Rodríguez S, Torres Castro M. Uso de resúmenes de evidencia para informar el tratamiento farmacológico de personas con sospecha o diagnóstico de infección respiratoria por SARS-CoV-2/COVID-19. Rev. Colomb. Nefrol. [Internet]. 14 de abril de 2020 [citado 23 de noviembre de 2020];7(Supl.2). Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/407